Korea Investment CORP increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 79.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 263,023 shares of the medical equipment provider’s stock after buying an additional 116,265 shares during the period. Korea Investment CORP owned approximately 0.09% of Hologic worth $11,936,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Victory Capital Management Inc. raised its position in shares of Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock valued at $172,363,000 after buying an additional 3,269,503 shares during the last quarter. American Century Companies Inc. raised its position in shares of Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock valued at $134,668,000 after buying an additional 2,204,085 shares during the last quarter. Bank of Montreal Can raised its position in shares of Hologic by 67.8% in the first quarter. Bank of Montreal Can now owns 3,206,769 shares of the medical equipment provider’s stock valued at $136,448,000 after buying an additional 1,295,885 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Hologic by 229.7% in the second quarter. Russell Investments Group Ltd. now owns 1,059,586 shares of the medical equipment provider’s stock valued at $48,100,000 after buying an additional 738,215 shares in the last quarter. Finally, Pictet Asset Management Ltd. raised its stake in Hologic by 69.4% in the first quarter. Pictet Asset Management Ltd. now owns 1,585,461 shares of the medical equipment provider’s stock valued at $67,461,000 after buying an additional 649,632 shares in the last quarter. Institutional investors own 94.43% of the company’s stock.
Shares of Hologic, Inc. (HOLX) traded down 1.40% during trading on Friday, hitting $37.42. 3,632,428 shares of the company traded hands. The stock has a market cap of $10.50 billion, a price-to-earnings ratio of 13.94 and a beta of 0.90. Hologic, Inc. has a one year low of $35.15 and a one year high of $46.80. The firm has a 50 day moving average price of $42.62 and a 200-day moving average price of $42.82.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping the consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period last year, the company posted $0.51 earnings per share. Analysts predict that Hologic, Inc. will post $2.01 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by BNB Daily and is the property of of BNB Daily. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/19/korea-investment-corp-buys-116265-shares-of-hologic-inc-nasdaqholx-updated.html.
Several analysts have recently commented on the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $49.00 price target on shares of Hologic in a research report on Wednesday, June 28th. Barclays PLC reiterated an “overweight” rating and issued a $53.00 price target (up from $50.00) on shares of Hologic in a research report on Monday, July 17th. BidaskClub lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Stifel Nicolaus reiterated a “buy” rating on shares of Hologic in a research report on Friday, July 14th. Finally, Bank of America Corporation reiterated a “neutral” rating and issued a $48.00 price target (up from $44.00) on shares of Hologic in a research report on Friday, July 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $48.64.
In related news, insider Peter J. Valenti III sold 10,005 shares of the firm’s stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $43.44, for a total transaction of $434,617.20. Following the completion of the sale, the insider now directly owns 20,994 shares in the company, valued at $911,979.36. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Lawrence M. Levy sold 9,193 shares of the firm’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $42.93, for a total transaction of $394,655.49. Following the sale, the director now owns 46,206 shares of the company’s stock, valued at $1,983,623.58. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 51,551 shares of company stock valued at $2,244,458. 0.79% of the stock is currently owned by corporate insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.